Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

Abstract Aims Despite substantial improvements over the last three decades, heart failure (HF) remains associated with a poor prognosis. The sodium‐glucose co‐transporter‐2 inhibitor empagliflozin demonstrated significant reductions of HF hospitalization in patients with HF independent of the presen...

Full description

Bibliographic Details
Main Authors: Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:ESC Heart Failure
Subjects:
Heart failure
Diabetes
SGLT2 inhibitors
31P‐MRS
Trial design
Empagliflozin
Online Access:https://doi.org/10.1002/ehf2.13406

Internet

https://doi.org/10.1002/ehf2.13406

Similar Items